Abstract 1047P
Background
AXA-042 is a novel synthetic, pegylated toll-like receptor (TLR) 2/6 agonist in development for the treatment of advanced solid tumors. Nonclinical pharmacology studies have demonstrated that AXA-042 functions through a multicellular mechanism, including activation of the pro-inflammatory innate immune response, reduction in immunosuppressive macrophages at the tumor site, activation of dendritic cells, and release of chemokines to facilitate T-cell recruitment. A first-in-human study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with a checkpoint inhibitor in subjects with advanced solid tumors is currently ongoing (ACTRN12622000993796).
Methods
AXA-042 is administered intravenously once every 21 days. After obtaining informed consent, whole blood and plasma samples were collected from patients pre- and post-treatment for assessment of AXA-042 pharmacokinetics and pharmacodynamic biomarkers. The Nanostring nCounter™ PanCancer IO 360 Panel and a 43-marker CYTOF panel were used to identify AXA-042 transcriptomic and immune modulation response signatures in whole blood samples collected 24- and 168-hours post dose. The OLINK Target 48 Cytokine Panel was used for the longitudinal assessment of cytokine modulation.
Results
Preliminary statistical analysis of immunomodulatory effects pre- and post- treatment is consistent with the proposed mechanism of AXA-042. Samples from the initial cohort of patients (n=3-6) displayed consistent transient induction of cytokines and chemokines, that returned to baseline within 2-8 hours post dose. Nanostring analysis confirmed TLR pathway engagement and revealed an induction of pro-inflammatory gene signatures, associated with myeloid cell activation and NFkB signaling. CYTOF characterization of immune subset activation and additional transcriptomic analyses are underway and will be presented.
Conclusions
AXA-042 demonstrates on-target biological activity in patient blood samples. Further biomarker analyses are ongoing and will be correlated with clinical activity in a larger number of patients.
Clinical trial identification
ACTRN12622000993796.
Editorial acknowledgement
Legal entity responsible for the study
Axelia Oncology.
Funding
Axelia Oncology.
Disclosure
A. Latifi, P. Kearney: Financial Interests, Personal, Full or part-time Employment: Axelia Oncology. P. Wabnitz, A. Galkin: Financial Interests, Personal, Financially compensated role: Axelia Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
1027P - An open-label, multicenter, phase I/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)
Presenter: Byoung Chul Cho
Session: Poster session 19
1028P - Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Presenter: Daphne Day
Session: Poster session 19
1029P - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Presenter: Anthony Olszanski
Session: Poster session 19
1030P - Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1031P - ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1032P - A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Presenter: Zhi Peng
Session: Poster session 19
1033P - First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
Presenter: Aung Naing
Session: Poster session 19
1034P - Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Presenter: Alexander Starodub
Session: Poster session 19
1035P - Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
Presenter: Ho Yeong Lim
Session: Poster session 19
1036P - A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Presenter: Junli Xue
Session: Poster session 19